DE1947222A1 - Dosage for ionic therapy - Google Patents
Dosage for ionic therapyInfo
- Publication number
- DE1947222A1 DE1947222A1 DE19691947222 DE1947222A DE1947222A1 DE 1947222 A1 DE1947222 A1 DE 1947222A1 DE 19691947222 DE19691947222 DE 19691947222 DE 1947222 A DE1947222 A DE 1947222A DE 1947222 A1 DE1947222 A1 DE 1947222A1
- Authority
- DE
- Germany
- Prior art keywords
- chemical
- new
- action
- create
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Chemisches Verfahren das erlaubt therapeutische Produkte unter einem neuen Wirkungsmechanismus und einer neuen Anwendungsform zu erstellen. Chemical process that allows therapeutic products under one to create a new mechanism of action and a new form of application.
Es ist bekannt, dass die übliche Arznei besonders durch Oral, Einspritzung oder unter Form einer Pommade gekennzeichnet ist.It is known that the usual medicine, especially by oral, injection or marked in the form of a pommade.
Das chemische Verfahren ist gebildet durch die Ausführungs-Methode, wo eine oder mehrere chemische Substanzen, nach einem geeigneten Prozess, therapeutische Wirkungen erzeugen müssen.The chemical process is formed by the execution method, where one or more chemical substances, after a suitable process, are therapeutic Have to produce effects.
Die 'lMethode'' entspricht den gesamten Mitteln, welche am geeignetsten sind um ein Ziel zu erreichen und die Ausführung entspricht dem Tätigkeitsprozess.The 'method' corresponds to the total means, which is the most suitable are to achieve a goal and the execution corresponds to the activity process.
Somit hat man den Rapport, chemische Substanzen, Ausführungsprozess und therapeutische Wirkungen.So you have the rapport, chemical substances, execution process and therapeutic effects.
Gegenstand der vorliegenden Erfindung liegt nun im bestimmten Gewicht Schwefel und Natrium chloratum in Verbindung zu bringen, wozu in bestimmter Dosis Katalysator und Verzögerer wie Silizium, Kohlenstoff und Kupferstaub zusammengesetzt sind, welche Mischung in einem Gewebebeutel eingeschlossen ist und an die Körperwärme und Feuchtigkeit gebracht - ohne den Körper zu berühren - chemische Reaktionen auslöst, beschleunigt und reguliert durch Oxydierung und Sublimierung beider therapeutischer Metalloide.The subject matter of the present invention now lies in the specific weight Bring sulfur and sodium chloratum in connection, including in a certain dose Catalyst and retarder composed of silicon, carbon and copper dust are what mixture is enclosed in a tissue bag and to the body heat and brings moisture - without touching the body - triggers chemical reactions, accelerates and regulates through oxidation and sublimation both therapeutic Metalloids.
Dieser Tätigkeitsprozess erzeugt Gasgemische mit S und Na-CL gesättigt, solche die ionisiert sind und oxygenierte Produkte wie H2, SO2 und SO3, samt den Gasgemischen der-thionischen Serie, sehr wirksame Agente, deren Multiplikation oder Reduzierung (Toleranz), sowie ihre physische, kinetische (cinetique) und medizinische Potentiell -von der bestimmten Dosis von jedem Element der chemischen Zusammensetzung abhängig sind.This activity process produces gas mixtures saturated with S and Na-CL, such which are ionized and oxygenated products such as H2, SO2 and SO3, including the gas mixtures the thionic series, very effective agents, their multiplication or reduction (Tolerance), as well as their physical, kinetic (cinetique) and medical potential -depending on the specific dose of each element of chemical composition are.
Somit, jenach der angewendeten Nenge von jedem Element der Mischung, erhält man auflösende, zerteilende, verändernde und stimulierende Wirkungen, welche die Entzündung und allergischen Prozess, sowie denjenigen des Stoffwechsels und sogar den Verteidigungsmechanismus des Organismus beeinflussen.Thus, depending on the applied quantity of each element of the mixture, one obtains dissolving, dividing, changing and stimulating effects, which the inflammation and allergic process, as well as those of metabolism and even affect the defense mechanism of the organism.
Sodann, dieses chemische Verfahren entwickelt die Ionisierung die zu der Ionotherapeutik führt und dies unabhängig von einem den Ions befremdenden elektrischen Stroms, aber ausschliesslich durch die Haut und Körperkomplex-Anziehungskraft auf die erzeugten und umgebenden Gasgemische. Dies erklärt die Wirkung der chemischen Zusammensetzung ohne in Kontakt mit dem Körper zu sein.Then, this chemical process develops the ionization leads to ionotherapy and this regardless of anything alienating the ion electric current, but exclusively through the skin and body complex attraction on the generated and surrounding gas mixtures. This explains the effect of the chemical Composition without being in contact with the body.
Die praktischen Proben erweisen eindeutig die positiven Resultate dieser neuen therapeutischen Mittel, welche mit unendlich kleiner, stetiger und optimaler Gassubstanz durch die Ionotherapeutik auf die Beinleiden, verschiedenen Rheumatismus und mehreren anderen Leiden, sowie als Spezifik der Schmerzen und der Entzundungen wirken. Damit ist das Produkt absolut unschädlich- und ohne Nebenwirkungen. Ist die Zusammensetzung vom Körper entfernt, wirkt sie nicht mehr und ihre aktive Substanz bleibt erhalten.The practical tests clearly show the positive results these new therapeutic agents, which with infinitely smaller, steady and optimal gas substance through ionotherapy on leg problems, various Rheumatism and several other ailments, as well as pain and the specific Inflammation work. This means that the product is absolutely harmless and has no side effects. If the composition is removed from the body, it no longer works and its active Substance is retained.
Bei dauernder Anwendung ist der Erschöpfungszustand der chemischen Reaktionen zwischen 4 und 6 Wochen begrenzt.With constant use, the state of exhaustion is the chemical one Reactions limited to between 4 and 6 weeks.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19691947222 DE1947222A1 (en) | 1969-09-18 | 1969-09-18 | Dosage for ionic therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19691947222 DE1947222A1 (en) | 1969-09-18 | 1969-09-18 | Dosage for ionic therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1947222A1 true DE1947222A1 (en) | 1971-04-01 |
Family
ID=5745819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19691947222 Pending DE1947222A1 (en) | 1969-09-18 | 1969-09-18 | Dosage for ionic therapy |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE1947222A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006133134A2 (en) | 2005-06-03 | 2006-12-14 | Prezacor, Inc. | Compositions comprising elemental metals and uses therefor |
| AU2012216851B2 (en) * | 2005-06-03 | 2015-05-07 | Prezacor, Inc. | Compositions comprising elemental metals and uses therefor |
| US10905894B2 (en) | 2013-03-15 | 2021-02-02 | Prezacor, Inc. | Therapeutic bioelectromagnetic fields, pain relief devices, and related methods |
-
1969
- 1969-09-18 DE DE19691947222 patent/DE1947222A1/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006133134A2 (en) | 2005-06-03 | 2006-12-14 | Prezacor, Inc. | Compositions comprising elemental metals and uses therefor |
| EP1904297A4 (en) * | 2005-06-03 | 2009-02-18 | Prezacor Inc | Compositions comprising elemental metals and uses therefor |
| AU2006255166B2 (en) * | 2005-06-03 | 2012-06-14 | Prezacor, Inc. | Compositions comprising elemental metals and uses therefor |
| EP2508341A1 (en) * | 2005-06-03 | 2012-10-10 | Prezacor, Inc. | Compositions comprising elemental metals and uses therefor |
| AU2012216851B2 (en) * | 2005-06-03 | 2015-05-07 | Prezacor, Inc. | Compositions comprising elemental metals and uses therefor |
| US9173900B2 (en) | 2005-06-03 | 2015-11-03 | Prezacor, Inc. | Compositions comprising elemental metals |
| US10195148B2 (en) | 2005-06-03 | 2019-02-05 | Prezacor, Inc. | Pain relieving compositions comprising elemental metals |
| US10905894B2 (en) | 2013-03-15 | 2021-02-02 | Prezacor, Inc. | Therapeutic bioelectromagnetic fields, pain relief devices, and related methods |
| US12102837B2 (en) | 2013-03-15 | 2024-10-01 | Gary A. Karpf | Therapeutic bioelectromagnetic fields, pain relief devices, and related methods |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0037488B1 (en) | Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes | |
| CH664896A5 (en) | METHOD FOR THE PRODUCTION OF PREPARATORS FASTENABLE TO THE SKIN. | |
| DE3115080C2 (en) | Medicines containing cytidine diphosphocholine and lecithin | |
| DE1947222A1 (en) | Dosage for ionic therapy | |
| DE69103624T2 (en) | PHARMACEUTICAL PREPARATIONS CONTAINING IPRIFLAVONE, METHOD FOR THE PRODUCTION AND THERAPEUTIC USE. | |
| DE2006696A1 (en) | Plaster or adhesive bandage | |
| Le Coz et al. | Occupational erythema-multiforme-like dermatitis from sensitization to costus resinoid, followed by flare-up and systemic contact dermatitis from β-cyclocostunolide in a chemistry student. | |
| Le Coz et al. | Allergic contact dermatitis from methoxy PEG-17/dodecyl glycol copolymer (Elfacos® OW 100). | |
| DE68911274T2 (en) | Therapeutic vaporized mixture and method for its production and use. | |
| WO2017050717A1 (en) | Substance for prophylaxis and treatment of infections by influenza viruses | |
| Bohn et al. | Contact allergy to trometamol. | |
| Sanchez-Rodriquez et al. | Cutaneous stings from Bartholomea annulata. | |
| DE2130775A1 (en) | Alkyl-bis-(2-hydroxylakyl or aralkyl or aryl)-sulphonium - sulphates - agents for the treatment of dermatoses | |
| Strobos et al. | Dermatitis caused by radio-frequency electromagnetic radiation. | |
| EP0842424B1 (en) | Process for determining the effectiveness and tolerance of a xenogenic substance administered to an organism | |
| DE3048154A1 (en) | NON-LONG-TERM ANTI-ARRHYTHMIC AGENTS, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | |
| EP0413792B1 (en) | Products containing a lithium salt and a tumour necrosis factor | |
| Gericke et al. | On a possible cocarcinogenic and immunosuppressive activity of phorbol in AKR-mice | |
| DE1109320B (en) | Device for combating deposits of radioactive fission products in organic living beings | |
| Rudolf | Klinische Effekte des therapeutischen Schlafentzugs | |
| DE918404C (en) | Process for the manufacture of a vaccine for the treatment of the paralysis that remains after child paralysis | |
| DE3340991A1 (en) | Use of dimethyl ether as propellant and solvent | |
| AT389049B (en) | Process for the production of pharmaceutical products which can be attached to uninjured skin, in particular of antispastic and antirheumatic products | |
| AT200256B (en) | Process for the production of medicinal products and disinfectants that contain free halogens or halogen-releasing compounds | |
| AT516952B1 (en) | drug |